EARNEST PARTNERS LLC - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.

Quarter-by-quarter ownership
EARNEST PARTNERS LLC ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2023$49
+2.1%
830.0%0.00%
Q2 2023$48
-17.2%
830.0%0.00%
Q1 2023$58
-69.1%
830.0%0.00%
Q4 2022$188830.0%0.00%
Q3 2022$0830.0%0.00%
Q2 2022$0830.0%0.00%
Q1 2022$0
-100.0%
830.0%0.00%
Q4 2021$1,0000.0%830.0%0.00%
Q3 2021$1,0000.0%830.0%0.00%
Q2 2021$1,000
-50.0%
830.0%0.00%
Q1 2021$2,000
+100.0%
830.0%0.00%
Q4 2020$1,0000.0%830.0%0.00%
Q3 2020$1,000
-50.0%
830.0%0.00%
Q2 2020$2,000
+100.0%
830.0%0.00%
Q1 2020$1,000
-50.0%
830.0%0.00%
Q4 2019$2,0000.0%830.0%0.00%
Q3 2019$2,000
-33.3%
830.0%0.00%
Q2 2019$3,0000.0%830.0%0.00%
Q1 2019$3,0000.0%830.0%0.00%
Q4 2018$3,000
-40.0%
830.0%0.00%
Q3 2018$5,000
+25.0%
830.0%0.00%
Q2 2018$4,000830.00%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q1 2022
NameSharesValueWeighting ↓
Camber Capital Management LP 3,500,000$60,060,0002.02%
ACT CAPITAL MANAGEMENT, LLC 161,500$2,772,0001.42%
Rhenman & Partners Asset Management AB 950,000$16,302,0001.11%
MAVERICK CAPITAL LTD 5,761,073$98,860,0000.93%
Birchview Capital, LP 72,000$1,236,0000.74%
Bellevue Group AG 4,101,404$70,380,0000.69%
CM Management, LLC 50,000$858,0000.62%
Duquesne Family Office 1,000,000$17,160,0000.42%
OSTERWEIS CAPITAL MANAGEMENT INC 373,368$6,407,0000.33%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 67,000$1,149,0000.30%
View complete list of NEKTAR THERAPEUTICS shareholders